Teva 3Q Revenues: $5.1 billion (+2%) 3Q Earnings: $706 million (loss of $84 million 3Q12) YTD Revenues: $14.9 billion (-1%) YTD Earnings: $876 million (-46%) Comments: Generic revenues were flat in the quarter at $2.5 billion (including API sales of $162 million). U.S. revenues were $1.1 billion, up 6%. European revenues were $812 million, down 1%. ROW revenues were $533 million, down 11%, primarily due to foreign currency effects. Specialty medicines revenues were $2.1 billion, up 3%, prim...